A study published in Alimentary Pharmacology Therapeutics in December 2017 compared the outcomes, pharmacokinetics, and immunogenicity of treatment intensification strategies in patients with Crohn disease (CD) who have lost clinical response to the anti–tumor necrosis factor (anti-TNF) therapy infliximab.
A study1 published in Alimentary Pharmacology Therapeutics in December 2017 compared the outcomes, pharmacokinetics, and immunogenicity of treatment intensification strategies in patients with Crohn disease (CD) who have lost clinical response to the anti—tumor necrosis factor (anti-TNF) therapy infliximab.
The presence of antibodies towards infliximab (ATI) is associated with lower infliximab trough concentrations and loss of response. The authors note that infliximab treatment intensification is effective for most patients with Crohn disease (CD) to restore response, however.
The researchers conducted a retrospective cohort study comprising 103 patients with CD who had a loss of response during infliximab maintenance therapy, and who subsequently received a double dose (10 mg/kg), and/or a shortened interval between infusions. Infliximab and ATI concentrations were measured in consecutive trough samples, just before (T0) and just after (T+1) treatment intensification.
Overall, 37% of the patients did not respond to dose intensification. Patients with ATIs above 282 ng/mL at T0 were significantly less likely to achieve T+1 therapeutic drug levels. Conversely, drug levels at the time of loss of response were less correlated with the outcome of the intervention.
In a linked editorial2, S. Ben-Horin, MD, sees these results as “underscoring once more the need to identify patients who will respond to dose optimization, while sparing this costly and potentially detrimental intervention from patients with low likelihood to respond.”
Ben-Horin also explains that the results of the study find that dose doubling is more effective in restoring a drug level of greater than 3 mcg/mL compared with interval shortening. Although the exact interval of dose shortening was not reported within the study, it could stand to reason that some patients may have had received an “every 6-week shortening” rather than interval halving, the latter of which the paper notes is comparable to dose doubling.
“Nonetheless, these data are in line with prior observations on overall non-inferiority of dose-doubling [versus] interval halving, and together they support double dosing over interval-shortening as a viable option which may save patients the need for another infusion visit and contribute to improved quality of life,” writes Ben-Horin.
The best strategy may ultimately be the prevention of loss of response by utilizing a proactive approach with drug and ATI measurements, among other factors.
“Data such as presented by Dreesen and colleagues are important for advancing our knowledge of how to implement pragmatic, yet rational-based approach to patients with [loss of response] to anti-TNFs.”
References
1. Dreesen E, Van Stappen T, Ballet V, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. Published online December 11, 2017. Aliment Pharmacol Ther. doi: 10.1111/apt.14452.
2. Ben-Horin S. Editorial: restoring therapeutic infliximab drug levels in patients with loss of response- pharmacokinetics and anti-drug antibodies as useful guidance tools. Published February 18, 2018. Aliment Pharmacol Ther. 2018. doi: 10.1111/apt.14489.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.